Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics
Journal of Biochemical and Molecular Toxicology · 2026-07 · 40 (7)
DOI: 10.1002/jbt.71021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 15.07.2026. Verfasst von Hongyan Ran und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, People's Republic of China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mitochondria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Scientific Fund of Chongqing Science and Technology Bureau.
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease driven by a complex interplay of mitochondrial dysfunction. These defects impair energy production, increases oxidative stress, and disrupts immune balance. Here we review three therapeutic classes that target mitochondrial pathways: antioxidants, metabolic modulators, and microbiota‐directed strategies. In UC, mitochondrial dysfunction creates a self‐perpetuating cycle through metabolic‐immune crosstalk, the leakage of mitochondrial DNA, and the redistribution of cardiolipin. Moreover, the gut microbiota and mitochondria engage in bidirectional crosstalk that amplifies intestinal inflammation. Encouragingly, agents that restore mitochondrial function have shown therapeutic benefit in preclinical and early clinical studies. Notable examples include the mitochondria‐targeted antioxidant MitoQ (currently in a Phase 2b trial for UC), ClpP (caseinolytic protease P) activators that reprogram T‐cell metabolism, and engineered probiotics that deplete pro‐inflammatory succinate. This review synthesizes current evidence on mitochondrial dysfunction in UC, bridging molecular mechanisms, immune‐metabolic interactions, and emerging therapeutics to propose a new treatment paradigm centered on mitochondrial restoration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, People's Republic of China.
- Chongqing Academy of Chinese Materia Medica, Chongqing University of Chinese Medicine, Chongqing, People's Republic of China.
ORCID-Profile: Fei Yin
Förderung
- Natural Scientific Fund of Chongqing Science and Technology Bureau
Zitieren
APA
Ran, H., Zhou, S., Zou, H., Deng, J., & Yin, F. (2026). Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics. Journal of Biochemical and Molecular Toxicology, 40(7). https://doi.org/10.1002/jbt.71021
Vancouver
Ran H, Zhou S, Zou H, Deng J, Yin F. Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics. Journal of Biochemical and Molecular Toxicology. 2026;40(7). doi:10.1002/jbt.71021
BibTeX
@article{Ran2026,
author = {Ran, Hongyan and Zhou, Siyuan and Zou, Hui and Deng, Juan and Yin, Fei},
title = {Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {7},
doi = {10.1002/jbt.71021}
}
EUVIMED